AbbVie vs Biogen
AbbVie (ABBV) and Biogen (BIIB) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $497B
- Last close
- $281.12
- 12 months
- +22.0%
- Market value
- $33.9B
- Last close
- $229.41
- 12 months
- +56.5%
At a glance
- By market value, AbbVie ($496.8B) is about 15 times Biogen ($33.9B).
- Over the last 12 months AbbVie's share price moved +22.0% and Biogen's +56.5%; against the S&P 500 that is +2.8 points and +37.4 points.
- In their last fiscal years AbbVie kept 6.9% of revenue as net income and Biogen 13.1%.
- In the last 90 days insiders reported 0 open-market purchases at AbbVie and 0 at Biogen; members of Congress disclosed 2 trades in AbbVie and 3 in Biogen.
- Next results: AbbVie Oct 30, 2026, Biogen Oct 28, 2026.
Share price over the last 12 months
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| AbbVie ABBVNYSE · Pharmaceuticals | Biogen BIIBNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $497B | $33.9B |
| Revenue, last fiscal year | $61.2B | $9.89B |
| Net income, last fiscal year | $4.23B | $1.29B |
| Net marginNet income as a share of revenue | 6.9% | 13.1% |
| Free cash flow | $17.8B | $2.05B |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Common questions
How do AbbVie and Biogen compare in size?
AbbVie has the larger market value: AbbVie $497B and Biogen $33.9B, at the last close.
Whose share price rose more over the last 12 months, ABBV or BIIB?
Over the last 12 months AbbVie moved +22.0% and Biogen +56.5%. Past price moves say nothing about the future.
Which has had more insider buying, AbbVie or Biogen?
Since 2006, Biogen insiders reported 34 open-market purchases against 25 for AbbVie. These are counts of what was filed, not a view on either stock.
Do members of Congress trade ABBV or BIIB?
In the last 12 months, members of Congress disclosed 12 trades in AbbVie (ABBV) and 9 in Biogen (BIIB).
When did insiders last buy ABBV and BIIB?
AbbVie: Mar 30, 2020. Biogen: Feb 18, 2026.
See the record behind any of these
Each company page opens free with one real filing and the counts of the last 12 months. OQRO Pro adds the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
AbbVie pageBiogen pageRare insider trades this weekAll comparisons
https://oqro.io/compare/abbv-vs-biib
